Drugs by active ingredient

Monthly reports by species, five years

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

2014 covers reports received through March 2026 only.

Signs listed in reports

share of thiabendazole reports listing the termall drugs containing thiabendazoleall dog reports

1. Uncoded sign[a sign with no matching dictionary term]25%14
2. Death8.9%5
3. Dropper, Abnormal8.9%5
4. Eye irritation8.9%5
5. Caps, Abnormal[a product quality report, not a sign in an animal]7.1%4
6. Vials, Leaking[a product quality report, not a sign in an animal]7.1%4
7. Accidental exposure[exposure that was not intended]5.4%3
8. Deafness NOS[NOS: not otherwise specified]5.4%3
9. External ear disorder NOS[NOS: not otherwise specified]5.4%3
10. Eye redness5.4%3
11. Lethargy[unusually tired or inactive]5.4%3
12. Anorexia[not eating]3.6%2
13. Application site erythema[reddened skin where the product was applied]3.6%2
14. Ataxia[unsteady, uncoordinated movement]3.6%2
15. Behavioural disorder NOS[behaviour change, type not specified]3.6%2
16. Deafness3.6%2
17. Diarrhoea[diarrhea]3.6%2
18. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]3.6%2
19. Elevated liver enzymes[liver enzymes above the normal range]3.6%2
20. Facial swelling3.6%2
21. Pinnal reddening3.6%2
22. Tachycardia[fast heart rate]3.6%2
23. Vomiting3.6%2
24. Abnormal birth weight1.8%1
25. Aggression1.8%1
26. Anaemia NOS[low red blood cell count]1.8%1
27. Anaphylaxis[sudden severe allergic-type reaction]1.8%1
28. Application site blister[blister where the product was applied]1.8%1
29. Application site hair change[hair change where the product was applied]1.8%1
30. Application site irritation[irritation where the product was applied]1.8%1

Top 30 of 74 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Coloured bar: reports naming thiabendazole. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Route of administration stated in reports: auricular (otic) (19), ophthalmic (10), oral (7).

In context

The thiabendazole pool is every report naming thiabendazole alone or in any combination; this single-ingredient set accounts for 2.7% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.